Gene expression profiling of IL1b induced primary human pulmonary artery endothelial cells (HPAECs) treated with or without I-BET762

Bromodomain inhibitor is a known chemotherapeutic that has been shown by others to be effective in treating pulmonary hypertension in vivo. The role of JQ1, a bromodomain inhibitor has been reported to regulate vascular smooth muscle cell proliferation and apoptosis but its effect on endothelial cells is not known. The objective of this experiment was to determine the effect of a similar bromodomain inhibitor I-BET762 on inflammation induced endothelial dysfunction. I-BET762 was chosen over other bromodomain inhibtors due to its favorable pharmacodynamics and pharmacokinetics in clinical trials. Interestingly, I-BET762 found to reverse various inflammation altered gene expression. We use Affymetrix Clairom S platform to determine the whole gene expression. HPAECs were induced with IL-1b with or without I-BET762 and appropriate control for 48h. There were three biological replicate for each group. The groups were Unstimulated with vehicle, Unstimulated with I-BET762, IL1b with vehicle and IL1b with I-BEt762